| Year |
Citation |
Score |
| 2024 |
Myers RM, Devine KJ, Li Y, Lawrence S, Barz Leahy A, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim G, Kulikovskaya I, Gonzalez V, Fraietta JA, et al. Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Advances. PMID 38386999 DOI: 10.1182/bloodadvances.2024012885 |
0.387 |
|
| 2024 |
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, et al. T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy. Nature Medicine. PMID 38266761 DOI: 10.1038/s41591-024-02826-w |
0.405 |
|
| 2023 |
Mackall C, Doan A, Mueller K, Chen A, Rouin G, Daniel B, Lattin J, Chen Y, Mozarsky B, Markovska M, Arias-Umana J, Hapke RR, Jung I, Xu P, Klysz D, ... ... Fraietta J, et al. FOXO1 is a master regulator of CAR T memory programming. Research Square. PMID 37986944 DOI: 10.21203/rs.3.rs-2802998/v1 |
0.351 |
|
| 2023 |
Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, Gohil M, Chen L, Hong SA, Ravikumar P, Rennels AK, Salas-Mckee J, Kong W, Ruella M, Davis MM, ... ... Fraietta JA, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 56: 2388-2407.e9. PMID 37776850 DOI: 10.1016/j.immuni.2023.09.001 |
0.469 |
|
| 2023 |
Noll JH, Levine BL, June CH, Fraietta JA. Beyond youth: Understanding CAR T cell fitness in the context of immunological aging. Seminars in Immunology. 70: 101840. PMID 37729825 DOI: 10.1016/j.smim.2023.101840 |
0.383 |
|
| 2023 |
Collins SM, Alexander KA, Lundh S, Dimitri AJ, Zhang Z, Good CR, Fraietta JA, Berger SL. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. Science Advances. 9: eadh2605. PMID 37467321 DOI: 10.1126/sciadv.adh2605 |
0.411 |
|
| 2023 |
Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, Jadlowsky JK, Plesa G, Siegel DL, Chew A, Levine BL, Berger SL, Moon EK, Albelda SM, Fraietta JA. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Reports. Medicine. 101053. PMID 37224816 DOI: 10.1016/j.xcrm.2023.101053 |
0.346 |
|
| 2023 |
Jung IY, Bartoszek RL, Rech AJ, Collins SM, Ooi SK, Williams EF, Hopkins CR, Narayan V, Haas NB, Frey NV, Hexner EO, Siegel DL, Plesa G, Porter DL, Cantu A, ... ... Fraietta JA, et al. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction. Cancer Discovery. PMID 37011008 DOI: 10.1158/2159-8290.CD-22-1175 |
0.418 |
|
| 2022 |
Collins MA, Jung IY, Zhao Z, Apodaca K, Kong W, Lundh S, Fraietta JA, Kater AP, Sun C, Wiestner A, Melenhorst JJ. Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL. Cancer Research Communications. 2: 1089-1103. PMID 36922932 DOI: 10.1158/2767-9764.CRC-22-0200 |
0.465 |
|
| 2022 |
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, ... ... Fraietta JA, et al. Author Correction: Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. PMID 36477542 DOI: 10.1038/s41586-022-05376-8 |
0.44 |
|
| 2022 |
Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discovery. PMID 36413381 DOI: 10.1158/2643-3230.BCD-22-0074 |
0.335 |
|
| 2022 |
Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, ... ... Fraietta JA, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine. 14: eabn7336. PMID 36350986 DOI: 10.1126/scitranslmed.abn7336 |
0.476 |
|
| 2022 |
Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, ... ... Fraietta JA, et al. Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer. Cancer Discovery. PMID 35904479 DOI: 10.1158/2159-8290.CD-21-1026 |
0.384 |
|
| 2022 |
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, ... ... Fraietta JA, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine. PMID 35314843 DOI: 10.1038/s41591-022-01726-1 |
0.347 |
|
| 2022 |
Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular Cancer. 21: 78. PMID 35303871 DOI: 10.1186/s12943-022-01559-z |
0.402 |
|
| 2022 |
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, ... ... Fraietta JA, et al. Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. PMID 35110735 DOI: 10.1038/s41586-021-04390-6 |
0.483 |
|
| 2021 |
Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, ... ... Fraietta JA, et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. The Journal of Clinical Investigation. 131. PMID 34396987 DOI: 10.1172/JCI145459 |
0.461 |
|
| 2021 |
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, et al. Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 33547459 DOI: 10.1038/s41591-021-01248-2 |
0.383 |
|
| 2020 |
Jacobson JM, Jadlowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Dimitri A, Levine BL, Veloso EA, Hwang WT, June CH. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33186691 DOI: 10.1016/j.ymthe.2020.11.007 |
0.481 |
|
| 2020 |
Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, Assenmacher CA, Radaelli E, Oh S, Wang B, Ellebrecht CT, Fraietta JA, Miloneǂ MC, Payne AS. Antigen-specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris. The Journal of Clinical Investigation. PMID 32817591 DOI: 10.1172/Jci138416 |
0.416 |
|
| 2020 |
Castellarin M, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, June CH. A rational mouse model to detect on-target off-tumor CAR T cell toxicity. Jci Insight. PMID 32544101 DOI: 10.1172/Jci.Insight.136012 |
0.381 |
|
| 2020 |
Lacey SF, Fraietta JA. First Trial of CRISPR-Edited T cells in Lung Cancer. Trends in Molecular Medicine. PMID 32536469 DOI: 10.1016/J.Molmed.2020.06.001 |
0.37 |
|
| 2020 |
Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clinical and Experimental Medicine. PMID 32333215 DOI: 10.1007/S10238-020-00628-1 |
0.52 |
|
| 2020 |
Wang W, Fasolino M, Cattau B, Goldman N, Kong W, Frederick MA, McCright SJ, Kiani K, Fraietta JA, Vahedi G. Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels. Proceedings of the National Academy of Sciences of the United States of America. PMID 32094195 DOI: 10.1073/Pnas.1919259117 |
0.49 |
|
| 2020 |
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, et al. CRISPR-engineered T cells in patients with refractory cancer. Science (New York, N.Y.). PMID 32029687 DOI: 10.1126/Science.Aba7365 |
0.467 |
|
| 2020 |
Fraietta JA. Abstract IA13: Reprogramming the epigenome for enhancing CAR T-cell antitumor efficacy Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Ia13 |
0.511 |
|
| 2020 |
Xu J, Gohil M, Stadtmauer E, Fraietta J, Gonzalez V, Salas-McKee J, Jadlowsky J, Gladney W, Lamontagne A, Fesnak A, Siegel D, Levine B, Lacey S, June C, Davis M. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) Cytotherapy. 22: S35-S36. DOI: 10.1016/J.Jcyt.2020.03.027 |
0.555 |
|
| 2019 |
Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. The Journal of Clinical Investigation. PMID 31845905 DOI: 10.1172/Jci130144 |
0.435 |
|
| 2019 |
Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances. 3: 2812-2815. PMID 31575532 DOI: 10.1182/Bloodadvances.2019000600 |
0.48 |
|
| 2019 |
Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ, Beatty GL. Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cellular and Molecular Gastroenterology and Hepatology. PMID 31398492 DOI: 10.1016/J.Jcmgh.2019.07.008 |
0.397 |
|
| 2019 |
van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. Blood. PMID 31076448 DOI: 10.1182/Blood.2018885863 |
0.545 |
|
| 2019 |
Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA. CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy. Human Vaccines & Immunotherapeutics. PMID 30735463 DOI: 10.1080/21645515.2019.1571893 |
0.52 |
|
| 2019 |
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An Introduction to Chimeric Antigen Receptor (CAR) T cell Immunotherapy for Human Cancer. American Journal of Hematology. PMID 30680780 DOI: 10.1002/Ajh.25418 |
0.508 |
|
| 2019 |
Wang M, Pruteanu I, Cohen AD, Garfall AL, Milone MC, Tian L, Gonzalez VE, Gill S, Frey NV, Barrett DM, Ruella M, Lacey SF, Svoboda J, Chong EA, Fraietta JA, et al. Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors Blood. 134: 622-622. DOI: 10.1182/Blood-2019-122513 |
0.464 |
|
| 2019 |
Wang M, Pruteanu I, Cohen AD, Garfall AL, Tian L, Lacey SF, Fraietta JA, Brogdon J, Davis M, Gonzalez VE, Levine BL, Siegel DL, Milone MC, Stadtmauer EA, June CH, et al. Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma Blood. 134: 1909-1909. DOI: 10.1182/Blood-2019-122396 |
0.543 |
|
| 2019 |
Vaskas AM, Fraietta JA, Long KB. Abstract C33: Effects of curcumin on pancreatic ductal adenocarcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-C33 |
0.388 |
|
| 2019 |
Gohil M, Dai A, Mackey S, Negorev D, Hennesy N, O'Rourke M, Lamontagne A, Holland D, Leskowitz R, Xu J, Ozerova M, McKee J, Pequignot E, Siegel D, Schuster S, ... ... Fraietta J, et al. Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells. Cytotherapy. 21: S19. DOI: 10.1016/J.Jcyt.2019.03.315 |
0.538 |
|
| 2019 |
Chen F, Fraietta JA, June CH, Xu Z, Joseph Melenhorst J, Lacey SF. Engineered T Cell Therapies from a Drug Development Viewpoint Engineering. 5: 140-149. DOI: 10.1016/J.Eng.2018.11.010 |
0.437 |
|
| 2018 |
Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, DeGaramo DA, Levine BL, Fraietta JA. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology. 9: 2740. PMID 30559740 DOI: 10.3389/Fimmu.2018.02740 |
0.528 |
|
| 2018 |
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine. PMID 30275568 DOI: 10.1038/S41591-018-0201-9 |
0.54 |
|
| 2018 |
Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, et al. Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunology Research. PMID 30030295 DOI: 10.1158/2326-6066.Cir-17-0405 |
0.519 |
|
| 2018 |
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. PMID 29849141 DOI: 10.1038/S41586-018-0178-Z |
0.564 |
|
| 2018 |
Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29807781 DOI: 10.1016/J.Ymthe.2018.05.003 |
0.349 |
|
| 2018 |
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 29713085 DOI: 10.1038/S41591-018-0010-1 |
0.545 |
|
| 2018 |
Kong W, Lacey SF, Melenhorst JJ, Fraietta JA. Biomarkers in chimeric antigen receptor T-cell therapy. Biomarkers in Medicine. PMID 29697279 DOI: 10.2217/Bmm-2018-0054 |
0.417 |
|
| 2018 |
Xu J, Melenhorst JJ, Fraietta JA. Toward precision manufacturing of immunogene T-cell therapies. Cytotherapy. PMID 29653875 DOI: 10.1016/J.Jcyt.2017.12.007 |
0.484 |
|
| 2018 |
Melenhorst JJ, Porter DL, Tian L, Lacey SF, Nobles CL, Fraietta JA, Frey NV, Kulikovskaya I, Gupta M, Young RM, Ambrose DE, Siegel DL, Bushman FD, June CH. Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones Blood. 132: 699-699. DOI: 10.1182/Blood-2018-99-117390 |
0.566 |
|
| 2018 |
Nobles CL, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey NV, Grupp SA, Siegel DL, Lacey SF, June CH, Bushman FD, Melenhorst JJ. Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) Blood. 132: 4548-4548. DOI: 10.1182/Blood-2018-99-117034 |
0.447 |
|
| 2018 |
Dancy E, Garfall AL, Cohen AD, Fraietta JA, Davis M, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, Melenhorst JJ. Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma Blood. 132: 1886-1886. DOI: 10.1182/Blood-2018-99-115319 |
0.536 |
|
| 2018 |
June CH, Scholler J, Ruella M, Fraietta J, Melenhorst JJ, Ren J, Zhao Y. Abstract IA20: Updates on CAR T Cells Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia20 |
0.536 |
|
| 2017 |
Hope JL, Stairiker CJ, Spantidea PI, Gracias DT, Carey AJ, Fike AJ, van Meurs M, Brouwers-Haspels I, Rijsbergen LC, Fraietta JA, Mueller YM, Klop RC, Stelekati E, Wherry EJ, Erkeland SJ, et al. The Transcription Factor T-Bet Is Regulated by MicroRNA-155 in Murine Anti-Viral CD8+ T Cells via SHIP-1. Frontiers in Immunology. 8: 1696. PMID 29358931 DOI: 10.3389/Fimmu.2017.01696 |
0.709 |
|
| 2017 |
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, et al. Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of Clinical Investigation. PMID 28714866 DOI: 10.1172/Jci89756 |
0.402 |
|
| 2017 |
Orlando E, Leary R, Lacey SF, Fraietta J, Bedoya F, Ambrose D, Wilcox N, Maude SL, Frey NV, Levine BL, Grupp SA, Porter DL, Young R, Winckler W, Morrissey M, et al. Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. Journal of Clinical Oncology. 35: 137-137. DOI: 10.1200/Jco.2017.35.7_Suppl.137 |
0.538 |
|
| 2017 |
Fraietta JA, Lacey SF, Orlando E, Pruteanu J, Gohil M, Wang Y, Boesteanu A, OConnor R, Ambrose DE, Hwang W, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Parakandi H, et al. Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia Blood. 130: 3181-3181. DOI: 10.1182/Blood.V130.Suppl_1.3181.3181 |
0.528 |
|
| 2017 |
Davis M, Fesnak A, Leskowitz R, McKee J, Ohayon Y, Corl C, Malykhin A, Fraietta J, Joseph Melenhorst J, June C, Schuster S, Levine B. Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL) Cytotherapy. 19: S118-S119. DOI: 10.1016/J.Jcyt.2017.02.190 |
0.424 |
|
| 2016 |
Fraietta JA, Schwab RD, Maus MV. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars in Oncology. 43: 291-9. PMID 27040708 DOI: 10.1053/J.Seminoncol.2016.02.006 |
0.521 |
|
| 2016 |
Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. IFN-gamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discovery. PMID 26896096 DOI: 10.1158/2159-8290.Cd-15-1032 |
0.324 |
|
| 2016 |
Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 44: 380-390. PMID 26885860 DOI: 10.1016/J.Immuni.2016.01.021 |
0.566 |
|
| 2016 |
Carey AJ, Gracias DT, Thayer JL, Boesteanu AC, Kumova OK, Mueller YM, Hope JL, Fraietta JA, van Zessen DB, Katsikis PD. Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 26873987 DOI: 10.4049/Jimmunol.1502126 |
0.761 |
|
| 2016 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Lacey SF, Milone M, Mato AR, Schuster SJ, et al. The Addition of the BTK inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26819453 DOI: 10.1158/1078-0432.Ccr-15-1527 |
0.482 |
|
| 2016 |
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. PMID 26813675 DOI: 10.1182/Blood-2015-11-679134 |
0.566 |
|
| 2016 |
Gracias DT, Boesteanu AC, Fraietta JA, Hope JL, Carey AJ, Mueller YM, Kawalekar OU, Fike AJ, June CH, Katsikis PD. Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. Journal of Immunology (Baltimore, Md. : 1950). PMID 26740110 DOI: 10.4049/Jimmunol.1501890 |
0.755 |
|
| 2016 |
Fraietta JA, Melenhorst JJ, Levine BL. Cell intrinsic PD-1 checkpoint blockade releases the brake on human chimeric antigen receptor (CAR) T cells for solid tumors Translational Cancer Research. 5. DOI: 10.21037/11200 |
0.427 |
|
| 2016 |
Fraietta JA, Lacey SF, Wilcox NS, Bedoya F, Chen F, Orlando E, Brogdon JL, Hwang W, Frey N, Young RM, Pequignot E, Ambrose DE, Levine BL, Bitter H, Porter DL, et al. Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia Blood. 128: 57-57. DOI: 10.1182/Blood.V128.22.57.57 |
0.538 |
|
| 2016 |
Ghassemi S, Prachi P, Scholler J, Nunez-Cruz S, Barrett DM, Bedoya F, Fraietta JA, Lacey SF, Levine BL, Grupp SA, June CH, Milone MC, Melenhorst JJ. Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control Blood. 128: 4549-4549. DOI: 10.1182/Blood.V128.22.4549.4549 |
0.515 |
|
| 2016 |
Long M, Beckwith KA, Do P, Bethany ML, Gordon G, Lehman AM, Maddocks KJ, Cheney C, Jones J, Andritsos LA, Awan FT, Fraietta JA, June CH, Maus MV, Woyach JA, et al. Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism Blood. 128: 3238-3238. DOI: 10.1182/Blood.V128.22.3238.3238 |
0.584 |
|
| 2016 |
Lacey SF, Xu J, Ruella M, Barrett DM, Kulikovskaya I, Ambrose DE, Patel PR, Reich T, Scholler J, Nazimuddin F, Fraietta JA, Maude SL, Gill SI, Levine BL, Nobles CL, et al. Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR Blood. 128: 281-281. DOI: 10.1182/Blood.V128.22.281.281 |
0.468 |
|
| 2016 |
Cogdill AP, Boesteanu A, Xu C, Haines K, Scholler J, Fraietta J, Zhao Y, Liu X, Morrissette J, Levine B, Lacey S, Loew A, Singh R, Brogdon J, O'Rourke DM, et al. Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B139 |
0.489 |
|
| 2016 |
Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells [Immunity 44, 380-390, (2016)] Immunity. 44: 712. DOI: 10.1016/j.immuni.2016.02.023 |
0.322 |
|
| 2015 |
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science Translational Medicine. 7: 275ra22. PMID 25696001 DOI: 10.1126/Scitranslmed.Aaa4963 |
0.467 |
|
| 2015 |
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone MC, Lacey SF, Mato A, Schuster SJ, et al. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma Blood. 126: 704-704. DOI: 10.1182/Blood.V126.23.704.704 |
0.407 |
|
| 2015 |
Castellarin M, Fraietta JA, Lee J, Scholler J, Zhao Y, June CH. A Novel Small Animal Model to Test on-Target Off-Tumor Cytoxicity of Adoptive Immune Therapies Blood. 126: 5432-5432. DOI: 10.1182/Blood.V126.23.5432.5432 |
0.462 |
|
| 2015 |
Cogdill AP, Boesteanu A, Haines K, Fraietta J, Scholler J, Loew A, Thekkat P, Brogdon J, Maus MV, June C, Johnson LA. Abstract B05: A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-B05 |
0.46 |
|
| 2015 |
Kawalekar OU, O'Connor RS, Fraietta J, Guedan S, Scholler J, Milone MC, June CH. 516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells Molecular Therapy. 23: S206-S207. DOI: 10.1016/S1525-0016(16)34125-9 |
0.493 |
|
| 2014 |
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace A, Thekkat P, Loew A, Chen TJ, Fraietta JA, Posey AD, Boesteanu AC, Cogdill AP, Engels B, et al. Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma Journal For Immunotherapy of Cancer. 2: 1-1. PMID 25746013 DOI: 10.1186/2051-1426-2-S3-O1 |
0.399 |
|
| 2014 |
Johnson BM, Fraietta JA, Gracias DT, Hope JL, Stairiker CJ, Patel PR, Mueller YM, McHugh MD, Jablonowski LJ, Wheatley MA, Katsikis PD. Acute exposure to ZnO nanoparticles induces autophagic immune cell death. Nanotoxicology. 1-12. PMID 25378273 DOI: 10.3109/17435390.2014.974709 |
0.672 |
|
| 2014 |
Fraietta JA, Mueller YM, Lozenski KL, Ratner D, Boesteanu AC, Hancock AS, Lackman-Smith C, Zentner IJ, Chaiken IM, Chung S, LeGrice SF, Snyder BA, Mankowski MK, Jones NM, Hope JL, et al. Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures. Antimicrobial Agents and Chemotherapy. 58: 7056-71. PMID 25224013 DOI: 10.1128/Aac.02991-14 |
0.743 |
|
| 2014 |
Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annual Review of Immunology. 32: 189-225. PMID 24423116 DOI: 10.1146/Annurev-Immunol-032713-120136 |
0.349 |
|
| 2014 |
Garfall AL, Fraietta JA, Maus MV. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discovery Medicine. 17: 37-46. PMID 24411699 |
0.316 |
|
| 2014 |
Kawalekar OU, O'Connor R, Guedan S, Fraietta J, Posey AD, Scholler J, Milone MC, June CH. Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells Blood. 124: 551-551. DOI: 10.1182/Blood.V124.21.551.551 |
0.561 |
|
| 2013 |
Fraietta JA, Mueller YM, Yang G, Boesteanu AC, Gracias DT, Do DH, Hope JL, Kathuria N, McGettigan SE, Lewis MG, Giavedoni LD, Jacobson JM, Katsikis PD. Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. Plos Pathogens. 9: e1003658. PMID 24130482 DOI: 10.1371/Journal.Ppat.1003658 |
0.783 |
|
| 2013 |
Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nature Immunology. 14: 593-602. PMID 23603793 DOI: 10.1038/Ni.2576 |
0.78 |
|
| 2013 |
Kawalekar OU, Posey AD, Fraietta J, Lee J, Scholler J, Zhao Y, June CH. Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells Blood. 122: 2902-2902. DOI: 10.1182/Blood.V122.21.2902.2902 |
0.557 |
|
| 2010 |
Fraietta JA, Mueller YM, Do DH, Holmes VM, Howett MK, Lewis MG, Boesteanu AC, Alkan SS, Katsikis PD. Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1. Antimicrobial Agents and Chemotherapy. 54: 4064-73. PMID 20625151 DOI: 10.1128/Aac.00367-10 |
0.752 |
|
| Show low-probability matches. |